The Potential Role for PARP Inhibitors in Prostate Cancer August 10, 2018 Precision oncology involves matching molecular aspects of a tumor to drugs targeting those pathways and is a routine consideration for patients with lung, ovarian, breast, colon, and hematologic cancers. PCa may be next with the use of Poly (ADP-ribose) Polymerase (PARP) inhibitors for patients with genetic defects in pathways regulating DNA repair, dominated by Breast Cancer Gene 2, Breast Cancer Gene 1, and Mutated in Ataxis Telangieectasia alterations.Read more.Source: Renal and Urology News Prostate Cancer News
Precision oncology involves matching molecular aspects of a tumor to drugs targeting those pathways and is a routine consideration for patients with lung, ovarian, breast, colon, and hematologic cancers. PCa may be next with the use of Poly (ADP-ribose) Polymerase (PARP) inhibitors for patients with genetic defects in pathways regulating DNA repair, dominated by Breast Cancer Gene 2, Breast Cancer Gene 1, and Mutated in Ataxis Telangieectasia alterations.Read more.Source: Renal and Urology News
